Article Text

Download PDFPDF

44 Immune signatures of severe immune-related adverse events detected by mass cytometry immune profiling in blood in patients with advanced melanoma treated with immunotherapy
  1. Connor Healy1,
  2. Magdalena Kovacsovics2,3,
  3. Natalia Sigal1,
  4. Li-Chun Cheng1,
  5. Shane Evans1,
  6. John Marsiglio3,
  7. Berit Gibson2,
  8. Yoko DeRose2,
  9. Annaleah Larson3,
  10. Carlos Medina1,
  11. Jolien Sweere1,
  12. Ramji Srinivasan1,
  13. Matthew Spitzer4,
  14. John Hyngstrom2 and
  15. Siwen Hu-Lieskovan2
  1. 1Teiko Bio, Salt Lake City, UT, USA
  2. 2Huntsman Cancer Institute, Salt Lake City, UT, USA
  3. 3University of Utah, Salt Lake City, UT, USA
  4. 4University of California San Francisco, Chan Zuckerberg Biohub, Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA


Background Immune-related adverse events (irAE) are major barriers of clinical management and further development of cancer immunotherapy. In this study, we used mass cytometry to characterize the immune system before and during presentation of severe (grade 3+ that required clinical intervention) irAE to identify cell signatures correlated with irAE development.

Methods We performed analysis on banked peripheral blood mononuclear cells (PBMCs) from 29 patients with melanoma undergoing checkpoint inhibitor (CPI) therapy, of which 18 developed severe irAEs (3 gastrointestinal, 5 endocrine, 4 cutaneous, 9 hepatobiliary, 4 musculoskeletal, 1 pulmonary irAEs and 1 acquired lipodystrophy) while 11 did not. Samples were taken at initiation of CPI (pre-treatment), before onset of irAE (pre-irAE) and at presentation of irAE (irAE max). The median number of CPI cycles per patient was 5 for patients with severe irAEs and 11 for patients without severe irAEs. We used a 44-marker mass cytometry panel designed to capture cell subsets and activation states across the innate and adaptive immune system, with both supervised analysis of manually gated immune cell subpopulations and unsupervised analysis by Clustering LARge Applications (CLARA) clustering.

Results At the peak of irAE presentation, patients with severe irAE demonstrated significantly more CD38+ (marker of immune activation) CD4+ central memory T cells (TCM), CD39+ (marker of tumor antigen-specificity) and HLA-DR+ (marker of activation) CD8 TCM cells, and CCR7+ (marker of migration) CD4+ T cells compared to patients with no or non-severe irEAs. Conversely, patients with severe irAEs had significantly fewer CD16+ NK cells and CD161+ (marker of inhibition) CD4+ T cells. Interestingly, patients with severe irAEs already had fewer CD16+ NK cells and CD161+ CD4+ T cells pre-treatment, and more CCR7+ CD4+ T cells pre-irAE. Presentation of severe irAEs was also correlated with significantly lower levels of TIGIT+ regulatory T (Treg) cells pre-treatment, and more CD4+ T naïve cells at all three timepoints.

Conclusions Development of severe irAE in melanoma could be the result of reduced inhibitory immune capacity pre-treatment, marked by fewer regulatory TIGIT+ Treg cells and CD161+ CD4+ T cells, leading to dysregulated increase in migratory CCR7+ CD4+ T, activated CD38+ and tumor-reactive CD39+ TCM cells, and activated CD16+ NK cells. This study demonstrates that high-dimensional immune profiling can detect novel blood-based immune signatures associated with presentation of severe irAEs.

Ethics Approval The study was approved by Huntsman Cancer Institute’s Ethics board, approval number IRB_00010924. Participants gave informed consent before taking part in the study.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.